VivoSeq
Other

Recurrent Epithelial Ovarian

0

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Recurrent Epithelial Ovarian is an early-stage landscape with 0 programs across 2 companies. The most active players are Amgen, Novakand Pharma AB.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

0 programs

PreclinicalN

Novakand Pharma AB

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed4 · 67%
Active, not recruiting1 · 17%
Not yet recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT04670068·4 enrolled
Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07489300·40 enrolled
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT01540565·52 enrolled
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Completed·Amgen logoAmgen·Phase 1·NCT00770536·103 enrolled
A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Completed·NNovakand Pharma AB·Phase 1/2·NCT06087289·18 enrolled
Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer
Completed·Amgen logoAmgen·Phase 2·NCT00479817·161 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)